Revenue from operations increased 7.37% year on year (YoY) to Rs 363.73 crore in Q1 FY27.

Profit before tax (PBT) rose 45.38% to Rs 129.12 crore in the June quarter from Rs 88.81 crore in the year-ago period.

Milind Thatte, managing director of P&G Health India, said the company began FY27 on a strong note, carrying forward the growth momentum from the previous fiscal. He attributed the performance to sustained top-line and bottom-line growth, driven by strong consumer response to the company's science-backed innovations, new consumer communication initiatives, and strengthened go-to-market and supply chain capabilities. He added that the company remains focused on delivering balanced growth and long-term value creation through its portfolio of trusted brands, product superiority, constructive disruption, productivity and an agile operating model.

Procter & Gamble Health is one of India's leading vitamins, minerals and supplements (VMS) companies. Its portfolio includes Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion.

The scrip declined 5.72% to Rs 6,089 on the BSE.